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Abstract
Background: Pancreatic panniculitis is a rare condition, which has only been described in relation with pancreatic
diseases up to now. It is characterized by necrotizing subcutaneous inflammation and is thought to be triggered
by adipocyte necrosis due to systemic release of pancreatic enzymes with consecutive infiltration of neutrophils.
We present the first case of a patient with pancreatic panniculitis caused by pancreatic-type primary acinar cell
carcinoma (ACC) of the liver and without underlying pancreatic disease.
Case presentation: A 73-year old Caucasian female patient was referred to our department with painful cutaneous
nodules persisting for eight weeks and with marked lipasemia (~15000 U/l; normal range <60 U/l). Four weeks prior,
several liver lesions had been detected. Empiric treatment with steroids did not show any effect. A biopsy of the skin
nodules revealed “pancreatic” panniculitis, while abdominal imaging with ultrasound, computed tomography and
magnetic resonance imaging detected no abnormal pancreatic findings. Ultrasound-guided biopsy of the liver lesions
showed infiltrates of an ACC. The patient died soon thereafter. Autopsy failed to reveal any other primary for the ACC,
so that a pancreatic-type ACC of the liver was diagnosed by exclusion.
One hundred thirty cases of pancreatic panniculitis published within the last 20 years are reviewed. ACC of the pancreas
is the most common underlying neoplastic condition. Patients with associated neoplasm are significantly older, take
longer to be diagnosed and have higher lipase levels than patients with underlying pancreatitis.
Extrapancreatic pancreatic-type ACC is very rare, but shows the same biological features as ACC of the
pancreas. It is believed to develop from metaplastic or ectopic pancreatic tissue. Up to now, no pancreatic
panniculitis in extrapancreatic ACC has been described.
Conclusion: Pancreatic panniculitis should always be included in the differential diagnosis of lipolytic panniculitic
lesions. It can be regarded as a facultative paraneoplastic phenomenon.
When suspected, a thorough work-up for identification of the underlying disease is mandatory and extrapancreatic
lesions (e.g. liver) should also be considered. While administration of octreotide or steroids can sometimes alleviate
symptoms, immediate treatment of the associated condition is the only effective management option.
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Background
Chiari was the first to describe the development of pan-
niculitic lesions in patients with pancreatitis in 1883 [1].
Since then, several case reports and small case series
have reported focal or generalized panniculitis in associ-
ation with pancreatic diseases like acute or chronic pan-
creatitis, pancreatic carcinoma (ductal adenocarcinoma,
acinar cell carcinoma, neuroendocrine carcinoma) or
intraductal papillary mucinous neoplasm (IPMN) [2–6].
Up to 45 % of patients with pancreatic panniculitis
show subcutaneous panniculitic nodules before the
causal disease is recognized [2]. Therefore, these nodules
can serve as an early and valuable clue to diagnosis of
the underlying condition and trigger measurement of
serum pancreatic enzymes, abdominal imaging or biopsy
procedures. Histologic evaluation of the cutaneous
lesions will typically reveal lobular neutrophilic necro-
tizing panniculitis intermingled with specific necrotic
anucleate adipocytes called “ghost cells” [7].
The mechanism underlying the formation of pan-
niculitic nodules in pancreatic panniculitis is poorly
understood. However, it is commonly believed that sys-
temically released pancreatic enzymes such as lipase and
amylase cause distant lipolysis and fat necrosis with con-
secutive inflammatory reaction [8]. This is supported by
the finding that the necrotic tissue stains positive for
lipase [9]. However, serum levels of pancreatic enzymes
do not correlate with clinical findings and similarly, in
vitro experiments suggest that this explanation is not
sufficient [10].
In addition to the cutaneous manifestation, arthritis is
often found in patients with pancreatic panniculitis, clin-
ically referred to as pancreatitis panniculitis polyarthritis
(PPP) syndrome. It is thought that pancreatic enzymes
are also able to trigger necrosis and inflammation in the
synovium [11]. Furthermore, there are reports about
panniculitis in the bone marrow, at submucosal sites or
within the thoracic or peritoneal cavity [2, 11, 12].
Acinar cell carcinoma (ACC) is a rare pancreatic
malignancy, representing about 1 % of all primary pan-
creatic neoplasms [13]. ACC is the most common malig-
nancy found in patients with pancreatic panniculitis [14]
and symptoms of pancreatic panniculitis can be found in
up to 16 % of ACC patients [4]. On very rare occasions,
pancreatic-type ACC can also arise as a primary
neoplasm at extrapancreatic locations, such as liver,
stomach, jejunum and colon [15–18]. In such cases,
extrapancreatic ACC is believed to originate from either
ectopic, metaplastic of transdifferentiated pancreatic
tissue and shares biologic features with primary pancre-
atic ACC [15].
Here, we report the first case of pancreatic panniculitis
in association with a primary pancreatic-type ACC of the
liver without underlying pancreatic disease. Moreover, we
present a review of case reports and case series of pancre-
atic panniculitis from the last 20 years, summarizing
important knowledge and data about this disease entity.
Case presentation
A 73-year-old Caucasian female patient was referred to
our department for further work-up of painful cutaneous
lesions (Fig. 1) and several masses within her liver.
Eight weeks prior, she had observed an erythematous
nodule on her right chest. Subsequently, similar cutane-
ous lesions had developed on her arms and legs, and
later also on her buttocks and back. She did not report
any abdominal complaints. Outpatient treatment with
topical and systemic steroids based on a suspicion of
erythema nodosum (EN) did not yield substantial effect.
Four weeks prior, several liver lesions had been de-
tected by ultrasound and were interpreted as metastases
of a previously treated breast cancer. Additional imaging
with computed tomography (CT) and magnetic reson-
ance imaging (MRI) had been carried out (Fig. 2) and
confirmed the liver lesions.
As the nodules on her skin continued to spread and
became increasingly painful, she was presented to the
Department of Dermatology in our clinic. There, an-
other attempt of steroids and an intensified local therapy
resulted in no improvement of her clinical condition.
Due to raising inflammatory parameters a work-up for
possible infectious causes and an antibiotic therapy with
piperacillin/tazobactam, and later with meropenem were
initiated. A colonoscopy revealed two small polyps, which
were completely removed. Pancreatic enzymes were mark-
edly elevated. A punch biopsy of one of the skin lesions
was obtained showing a lobular necrotizing panniculitis
with “ghost cells” compatible with pancreatic panniculitis
(Fig. 3). CT, MRI and repeated ultrasound examinations
(Fig. 4) did not reveal any pathological findings in the pan-
creas. In contrast enhanced CT multiple sharply-bounded
liver lesions were visualized in both liver lobes. Compared
Fig. 1 Several panniculitic lesions on the right leg of the patient,
one of them (→) shortly after having spontaneously drained
brownish-oily fluid
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with the CT obtained during outpatient care, the lesions
had progressed in size and measured from 1 cm to 6 cm.
The perfusion pattern was non-hypervascular and the
density was hypointense, partly comparable with the
density of water. No necrotic areas were described within
the lesions.
Because of a progressive worsening of her clinical
condition and increasing laboratory markers of inflam-
mation, the patient was referred to our Department of
Internal Medicine. She complained about intensive pain
all over her skin and required increasing dose rates of
opioid analgetics. She did not report any weight loss,
night sweats, fever, nausea or vomiting, abdominal pain
or problems with food intake. Her past medical history
was remarkable for invasive ductal breast cancer diag-
nosed in 1982 with local recurrences in 1990 and 2008.
Moreover, a superficial spreading malignant melanoma
had been treated in 2011 and a coronary artery disease
with percutaneous coronary intervention in 2008 was re-
ported. Family history was significant for malignant mel-
anomas in all siblings and her mother. Continuous
medication included acetyl salicylic acid, lercanidipine,
metoprolol, enalapril and pravastatin with no recent
change. No allergic condition was known.
On examination she was in poor general condition
(ECOG performance status 4), tachycardic (102 bpm),
slightly tachypnoeic (22/min) and normotensive (128/
78 mmHg). Her temperature was 36.9 °C. Subcutaneous
erythematous and painful nodules of 2–5 cm size were
noticed throughout her integument. Some of them were
spontaneously draining a brownish oily fluid. Moreover,
more than 200 melanocytic nevi were observed on her
skin. Examination of the head, especially focusing on the
salivary glands was unremarkable. There was no pain on
abdominal palpation, the liver was palpable 2 cm under
the right costal arch and bowel sounds were normal.
There was a positive tap sign on both patellae.
Laboratory results of interest were: leukocyte count
21.5 * 10^3/μl (ref. 4–10 * 10^3/μl), hemoglobin 10.0 g/dl
(ref. 12–16 g/dl), ASAT 52 U/l (ref. < 35U/l), GGT 235 U/l
(ref. <40 U/l), AP 186 U/l (ref. 35–105 U/l), lipase
14747 U/l (ref. < 60 U/l) and CRP 237 mg/l (ref. < 5 mg/l).
Alpha-Amylase, uric acid, ACE, CEA, CA19-9 and AFP
were within normal range. Serology for Yersinia enteroco-
litica and pseudotuberculosis was negative, as well as
testing for Mycobacterium tuberculosis and atypical
mycobacteria. Rheumatologic testing including ANAs and
ANCAs was unremarkable.
Screening for possible infectious foci did not reveal any
other source explaining the elevated CRP. Therefore, it
was attributed to the skin lesions, which displayed clinical
signs of inflammation and were partly draining pus in the
further course. However, as microbiological evaluation
was not able to prove any causative organism and inflam-
mation markers were not substantially declining despite
escalation of antibiotic treatment with additional vanco-
mycin, skin lesions were classified as sterile. Leukocytosis
was explained by concomitant steroid therapy.
Ultrasound displayed several liver lesions in both lobes
with a maximum size of 53 mm. The pancreas was
Fig. 2 Imaging of the liver lesions (→) with ultrasound (a) and CT (b)
Fig. 3 Biopsy from a skin lesion showing lobular neutrophilic,
necrotizing panniculitis and so called “ghost cells” (→)
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homogeneous and free of focal lesions. The pancreatic
duct was not dilated and no avascular areas could be de-
tected upon administration of ultrasound contrast agent.
Ultrasound-guided puncture of one of the liver masses
was performed leading to the histopathological diagnosis
of a pancreatic-type ACC.
Unfortunately, the condition of the patient had se-
verely deteriorated in the meantime with further
exacerbation of pain, increasing tachycardia and
hypotension. Therefore, no tumor-specific treatment
could be initiated. The patient died ten days after admis-
sion to our ward.
Pathological and autopsy findings
Histopathological analysis of the core biopsy obtained
from the liver mass revealed a cellular epithelial neo-
plasm composed of monomorphic polygonal or rounded
cells arranged in compact acinar and trabecular struc-
tures (Fig. 5a, b). Immunohistochemical study revealed
strong expression of pancytokeratin (KL-1) with variable
expression of CK7 and diffuse strong cytoplasmic ex-
pression of trypsin (Fig. 5c), but lipase and amylase were
negative. All other markers in the differential diagnosis
were negative (CK5, CK20, HepPar-1, Synaptophysin,
Chromogranin A, NSE, CD56, TTF1, ER, PR, protein
S100, GATA3 and PAX8). These findings including in
particular the strong and specific expression of trypsin
confirmed the diagnosis of pancreatic-type ACC in
the liver.
Autopsy confirmed several liver masses measuring up
to six centimeters in size. There was no evidence of a
salivary gland tumor or a primary pancreatic tumor.
Additionally, review of the slides from the patient’s pre-
vious breast cancer confirmed a breast cancer of no spe-
cial type and excluded the possibility of acinar-like
differentiation. Thus, the previous breast cancer was also
unrelated to the patient's ACC. Cause of her death was
attributed to multiorgan failure due to severe systemic
inflammatory response syndrome.
Final diagnosis was pancreatic panniculitis due to pri-
mary pancreatic-type acinar cell carcinoma of the liver.
Taking into account the conspicuous accumulation of
malignancies in our patient and her family, genetic analysis
for familial atypical multiple mole-melanoma (FAMMM)
syndrome was recommended to her relatives.
Review of literature
In addition to the presented case, 130 reports on pancre-
atic panniculitis were identified in the English literature
between January 1994 and November 2014 by using the
search terms “pancreatic panniculitis”, “subcutaneous fat
necrosis AND pancreas” and “lipase hypersecretion
syndrome” in PubMed and by checking results for
appropriate cross-references.
Including the above case, all 131 cases (Table 1) were
analyzed in respect to available data on age and gender
of the patients, the underlying condition, additional
symptoms, the sequence of the appearance of panniculi-
tis and the diagnosis of the underlying disease, labora-
tory values and the outcome. The stated percentages
refer to the respective number of cases including data
on the analyzed parameter. Statistical analysis was
Fig. 4 Abdominal imaging showing no evidence of pancreatic
pathology. a CT. b MRI. c ultrasound
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performed with IBM SPSS Statistics (IBM, Armonk, NY,
USA) using Student’s T-test or Fisher’s exact test where ap-
plicable. p < 0.05 was considered significant. Graphs were
generated with SigmaPlot (Systat, San Jose, CA, USA).
Overall, 65 cases (49.6 %) were due to acute or chronic
pancreatitis and 60 cases (45.8 %) had an underlying
neoplastic condition. In six cases (4.6 %) other reasons
were present, e.g. pancreas transplant rejection or pan-
creaticovascular fistula (Table 2).
Patients with pancreatic panniculitis had a mean age
of 54.8 years. Yet, patients with neoplastic causes were
significantly older than individuals with pancreatitis
(Fig. 6a). 57.4 % of the patients were male with no differ-
ence in sex distribution between underlying pancreatitis
and malignancy.
In 48.9 %, cutaneous lesions were noted prior to the
diagnosis of the underlying disease. The mean duration
from appearance of the first lesion to diagnosis was
85 days +/− 110 days (range: 2–540 days; median
42 days). This period was significantly longer when pan-
creatic panniculitis was due to a neoplasm than when a
pancreatitis was present (Fig. 6b). Moreover, the portion
of patients developing panniculitis before the diagnosis
of the underlying condition was by trend higher in pa-
tients with neoplastic disease (66.7 %) than in patients
with pancreatitis (48.3 %; p = 0.06).
A PPP syndrome with additional signs of arthritis was
present in 49 cases (37.4 %).
One hundred twelve case reports (85.5 %) contained
information on the serum levels of at least one pancre-
atic enzyme. In all but two of these reports (1.8 %) either
amylase or lipase were elevated – in one of these two
cases only amylase had been measured. The mean level of
lipase was 11560 U/l +/− 19010 U/l (range 7–89700 U/l,
median 3942.5 U/l). Again, patients with pancreatitis and
neoplastic conditions differed markedly with tumor pa-
tients having significantly higher lipase levels (Fig. 6c).
ROC analysis identified a lipase level of 4414 U/l as best
cut-off value with higher values having a sensitivity of
73.0 % and a specificity of 82.1 % for the diagnosis of a
neoplastic cause (AUC = 0.785, 95 % CI 0.68 to 0.89).
Only limited data was available concerning survival
and follow-up. 12 patients with pancreatitis (21.4 %) died
from complications. For underlying malignancy, follow-
up data was available for 29 patients. A Kaplan-Meier
plot of survival was computed, yielding a median sur-
vival of 4.75 months after appearance of the first skin le-
sion (Fig. 6d).
Discussion
Panniculitis is a clinical finding, which can be caused by
various etiologic factors including infectious, immuno-
logic and neoplastic conditions [19–21].
In our case, numerous causes could be excluded, while
others were very unlikely: No infectious organism could
be detected directly or indirectly. Continuous medica-
tion was unchanged and unsuspicious for causing ery-
thema nodosum. Imaging had not yielded any evidence
Fig. 5 Histomorphology and immunohistochemistry of the liver
tumor (from core biopsy). a core biopsy of the liver showing liver
tissue adjacent to the acinar cell carcinoma, haematoxylin/eosin
staining, 10-fold magnification. b compact acinar structures and
trabeculae seen at higher magnification, haematoxylin/eosin staining,
40-fold magnification. c The tumor cells stained strongly for trypsin,
40-fold magnification
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Table 1 Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014
Patient Ref. Age Sex Underlying condition Outcome of skin lesions/follow-up
1 our pat. 73 f ACC of the liver death ten weeks after first skin lesion
2 [53] 55 m metastatic pancreatic NEC n.r.
3 [54] 38 m acute pancreatitis resolution
4 [7] 63 m acute pancreatitis resolution
5 [55] 81 f hemosuccus pancreaticus death 19 weeks after first skin lesion
6 [56] 26 f acute pancreatitis resolution
7 [57] 27 f acute pancreatitis resolution
8 [58] 34 m chronic pancreatitis n.r.
9 [59] 63 f acute pancreatitis resolution
10 [60] 83 m pancreatic ACC resolution of skin lesions after surgery, death
34 months after first skin lesion
11 [60] 75 m Acute pancreatitis resolution
12 [60] 60 m Large pancreatic neoplasm n.r.
13 [61] 68 f metastatic pancreatic ACC death six months after first skin lesion
14 [62] 61 f acute pancreatitis resolution
15 [63] 63 f acute pancreatitis resolution
16 [64] 49 m acute pancreatitis resolution
17 [47] 69 m hepatic metastasis of previous-ly resected
pancreatic ACC
resolution after metastasectomy, follow-up n.r.
18 [65] 71 f chronic pancreatitis with pseudocyst n.r.
19 [66] 66 f serous cystadenoma of the pancreas n.r.
20 [67] 39 m chronic pancreatitis death six weeks after first skin lesion
21 [68] 20 f pseudopapillary pancreatic tumor, chronic
pancreatitis
death eleven weeks after first skin lesion
22 [8] 38 f acute pancreatitis resolution
23 [69] 56 f acute pancreatitis death within a few days
24 [70] 79 m pancreatic ACC n.r.
25 [71] 17 f acute pancreatitis resolution
26 [72] 54 m pancreatic ACC Response to octreotide, regression of skin
lesions after resection, follow-up two months
(i.e. eleven months after first skin lesion)
27 [73] 81 f pancreatic tumor with hepatic metastases n.r.
28 [74] 64 m anastomotic leakage after Whipple procedure death 50 days after first skin lesion
29 [75] 79 f pancreatic ACC regression after resection, follow-up 14 months
after resection (i.e. 16 months after first skin
lesion)
30 [35] 60 f pancreatic adenocarcinoma n.r.
31 [35] 58 m malignant neoplasia of the tail of the pancreas n.r.
32 [76] 44 f pancreas transplant rejection resolution
33 [77] 63 f metastatic pancreatic adenocarcinoma n.r.
34 [78] 38 m pancreatic pseudocyst-inferior vena cava fistula resolution after Roux-en-Y pseudocyst-
jejunostomy
35 [40] 82 m pancreatic ACC death 2.5 months after first skin lesion
36 [46] 79 m pancreatic ACC death two months after first skin lesion
37 [79] 2,5 m acute pancreatitis with pseudocyst n.r.
38 [80] 45 m chronic pancreatitis resolution after placement of endoprothesis
39 [81] 18 w acute pancreatitis resolution
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Table 1 Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014
(Continued)
40 [82] 10 w acute pancreatitis with pseudocyst resolution after endosonographic cysto-
gastrostomy
41 [83] 69 m gastric adenocarcinoma with pancreas
metastasis
death 14 weeks after first skin lesion
42 [84] 58 m pancreatic pseudocyst-portal vein fistula death five days after admission
43 [85] 84 m pancreatic tumor death two months after first skin lesion
44 [86] 40 m chronic pancreatitis n.r.
45 [87] 84 f acute pancreatitis, liver lesions ten years after
resection of colonic carcinoma
initially resolution, death three months later
46 [2] 65 f acute pancreatitis death from gangrenous cholecystitis
47 [2] 64 f acute pancreatitis resolution
48 [2] 70 f pancreatic carcinoma death
49 [2] 58 m pancreatic carcinoma death
50 [2] 21 f pancreatic carcinoma death
51 [2] 75 m acute pancreatitis death
52 [2] 75 f acute pancreatitis resolution
53 [2] 44 m chronic pancreatitis resolution
54 [2] 63 m pancreatic carcinoma death
55 [2] 72 m pancreatic carcinoma death
56 [2] 60 m pancreatic carcinoma n.r.
57 [88] 35 m chronic pancreatitis n.r.
58 [89] 7 m acute pancreatitis resolution
59 [14] 61 m metastatic NEC of unknown primary site death a few weeks after first skin lesion
60 [42] 50 f metastatic ACC regression of skin lesions and tumor under
octreotide, gemcitabine, streptozocin and
doxorubicin; return after discontinuation;
response to restart of therapy; follow-up
9 months after first skin lesion
61 [90] 74 m pancreatic ACC death 3.75 months after first skin lesion
62 [91] 61 m metastatic ACC n.r.
63 [92] 79 m metastatic pancreatic NEC Regression under cefazolin, dexamethasone and
NSAID; death 13 months after first skin lesion
64 [93] 50 m acute pancreatitis death 38 days after first skin lesion
65 [94] 4 m acute pancreatitis resolution
66 [11] 45 m acute pancreatitis Regression under NSAID and prednisone
67 [95] 72 m acute pancreatitis resolution
68 [96] 52 f pancreatic carcinoma death six months after first skin lesion
69 [97] 29 m acute pancreatitis resolution
70 [23] 75 f hepatic metastases of adeno-carcinoma of un-
known origin
death 15 weeks after first skin lesion
71 [6] 78 m metastatic pancreatic NEC death two months after first skin lesion
72 [6] 75 m pancreatic adenocarcinoma regression under irradiation, follow-up n.r.
73 [98] 67 f IPMN partial pancreatectomy, follow-up n.r.
74 [99] 51 m chronic pancreatitis regression of skin lesions under conservative
treatment
75 [100] 49 f pancreas transplant rejection resolution
76 [101] 89 f acute pancreatitis resolution
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Table 1 Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014
(Continued)
77 [42] 59 m hepatic metastases of pre-viously resected
pancreatic ACC
death several weeks after first skin lesion
78 [102] 67 m metastatic pancreatic adenocarcinoma regression under irinotecan, cisplatin, mito-mycin;
death twelve months after first skin lesion
79 [103] 62 f IPMN resection, follow-up n.r.
80 [22] 60 m metastatic pancreatic acinar cell
cystadenocarcinoma
death seven weeks after admission
81 [104] 13 m chronic pancreatitis with pseudocyst regression after cystogastrostomy
82 [41] 72 m pancreatic NEC regression after resection, no reappearance with
liver metastases, death 15 months after first skin
lesion
83 [25] 58 m HCC death four months after first skin lesion
84 [105] 88 m metastatic pancreatic NEC Death eight weeks after first skin lesion
85 [106] 42 f acute pancreatitis resolution
86 [107] 63 m chronic pancreatitis resolution after distal pancreatectomy and
pancreatic duct dilation
87 [108] 34 m acute pancreatitis resolution
88 [109] 21 f acute pancreatitis death from retroperitoneal hemorrhage
89 [110] 61 f metastatic pancreatic ACC death one year after first skin lesion
90 [3] 70 f IPMN resolution after resection
91 [3] 53 f IPMN resolution after resection
92 [111] 37 f acute pancreatitis with pseudocyst resolution after surgery
93 [111] 50 m acute pancreatitis with pseudocyst resolution after stone extraction from the
pancreatic duct
94 [112] 71 m pancreatic adenocarcinoma n.r.
95 [113] 60 f pancreatic ACC regression after distal pancreatectomy,
follow-up 28 months after first skin lesion
96 [113] 54 m pancreatic ACC death six weeks after first skin lesion
97 [114] 56 m chronic pancreatitis n.r.
98 [115] 53 m actue pancreatitis resolution
99 [48] 67 m metastatic pancreatic ACC Regression after TACE of four liver metasta-ses,
death 14 weeks after first skin lesion
100 [116] n.r. n.r. chronic pancreatitis resolution after placement of pancreatic duct
stent
101 [117] 31 m acute pancreatitis resolution
102 [118] 57 f acute pancreatitis resolution
103 [119] 60 f pancreatic ACC resolution after resection, follow-up n.r.
104 [120] 41 m acute pancreatitis death 22 days after admission
105 [44] 79 f metastatic pancreatic ACC Death 20 weeks after first skin lesion
106 [121] 45 m chronic pancreatitis resolution
107 [122] 59 f acute pancreatitis resolution
108 [123] 81 m pancreatic ACC n.r.
109 [124] 69 m pancreatic ACC n.r.
110 [125] 15 f acute pancreatitis death nine days after first skin lesion
111 [126] 49 m acute pancreatitis regression under antibiotic treatment, then
slight progression, follow-up seven weeks
112 [127] 66 m pancreatic ACC resolution after resection, follow-up n.r.
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of malignancy other than the finally diagnosed ACC.
Rheumatologic disease was judged unlikely based on
consultation with a rheumatologist.
Therefore, regarding laboratory data and histologic
results pancreatic panniculitis was the only possible
diagnosis.
Our case of pancreatic panniculitis is noteworthy for
two reasons: The absence of pancreatic disease and the
extrapancreatic manifestation of pancreatic-type ACC.
The combination of both has not been previously de-
scribed in the literature. Pancreatic panniculitis without
definite proof of pancreatic disease is found in four cases
in the literature: Beltraminelli et al. [22] report a case of
acinar cell cystadenocarcinoma of presumably pancreatic
origin metastatic to the liver. However, clear evidence of
a pancreatic primary tumor was absent on imaging.
Freireich-Astmann et al. [23] describe the history of a
patient with hepatic metastases of an adenocarcinoma of
unknown primary. CT did not show any pancreatic
lesion and immunohistochemistry was negative for CA19-9
and CK19. Aznar-Oroval et al. present a case of gastric
adenocarcinoma with hepatic metastases in association
with pancreatic panniculitis, but without clinical or
radiologic findings of pancreatic disease [24]. And finally,
Table 1 Overview of pancreatic panniculitides described in English literature between January 1994 and November 2014
(Continued)
113 [128] 67 m chronic pancreatitis death two months after first skin lesion
114 [12] 69 m pancreatic ACC resolution after distal pancreatectomy and
adjuvant radio-chemotherapy, follow-up
6 months
115 [129] 29 f acute pancreatitis resolution
116 [130] 29 m pancreatic pseudocyst-portal vein fistula no new lesions after surgery
117 [131] 75 m pancreatic tumor Death several months after first skin lesion
118 [131] 39 m chronic pancreatitis with pseudocyst n.r.
119 [132] 62 m acute pancreatitis resolution
120 [133] 77 f pancreatic tumor death five months after first skin lesion
121 [134] 54 f chronic pancreatitis resolution after ESWL and endoscopic dilation
of the pancreatic duct
122 [135] 47 f acute pancreatitis resolution
123 [136] 7 m acute pancreatitis n.r.
124 [137] 69 m chronic pancreatitis with pseudocyst resolution
125 [138] 33 f acute pancreatitis n.r.
126 [139] 46 f chronic pancreatitis death four months after first skin lesion
127 [140] 55 m chronic pancreatitis n.r.
128 [5] 62 m acute pancreatitis resolution
129 [141] 61 f metastatic ACC resolution after surgery, follow-up n.r.
130 [142] 80 m pancreatic ACC resolution after surgery, death from metastatic
disease after 18 months
131 [143] n.r. m pancreatic ACC n.r.
Table 2 Etiology of pancreatic panniculitis
Pancreatitis Neoplastic conditions Other
Acute 34.4 % pancreatic ACC 19.8 % fistula 2.3 %
Chronic 15.3 % n. r. 9.9 % transplant rejection 1.5 %
NEC 4.6 %
adeno-carcinoma 3.8 % anastomotic leakage 0.8 %
IPMN 3.1 %
other 4.6 %
Total 49.6 % total 45.8 % total 4.6 %
While near half of the cases are caused by acute or chronic pancreatitis, another 45.8 % are associated with neoplastic conditions (other: acinar cystadenocarcinoma,
ACC of the liver, serous cystadenoma, HCC, gastric carcinoma with pancreatic infiltration, adenocarcinoma of unknown primary)
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Corazza et al. [25] report about a patient with multifocal
hepatocellular carcinoma (HCC) and missing pancreatic
lesions in CT.
However, in all cases, no autopsy for definite verifica-
tion of the absence of pancreatic disease was performed.
Amylase or lipase were elevated in each of the cases, but
could not be explained by clinical, radiologic or histo-
logical findings in all but Beltraminelli et al.’s case. While
existence of a primary hepatic acinar cell cystadenocarci-
noma should have been discussed in this case, findings
are inconclusive in the other three.
The HCC described by Corazza showed “trabecular
structures and acinar aspects”, features suggestive of or
consistent with ACC [15]. As immunohistochemistry is
not reported, the possibility of a pancreatic-type ACC of
the liver cannot be fully excluded in that case.
Primary extrapancreatic ACC is extremely rare and
only six cases of ACC originating in the liver have been
described to date [15, 26, 27]. Diagnosis of pancreatic-
type ACC originating from the liver requires exclusion
not only of an occult pancreatic primary, but also of
primaries at other possible sites, such as breast [28] or
salivary glands [29]. In our case, neither clinical nor
radiological evidence for another primary was present,
which was finally verified by autopsy findings. Moreover,
re-analysis of the samples of the previously treated
breast cancer excluded a hitherto undiscovered acinar
cell carcinoma of the breast.
Because of the rarity of primary ACC of the liver, no
typical pattern can be specified in the different imaging
modalities up to now. So far, most of the cases described
were initially misclassified as one of the most common
primary liver malignancies, such as HCC or cholangio-
cellular carcinoma (CCC), due to their imaging appear-
ance. Moreover, a recent study on imaging findings in
pancreatic ACC also reported a high variability in several
parameters analyzed [30]. Thus, a thorough histological
work-up of specimens after a resection or core biopsy is
required to ensure the correct diagnosis [15, 26, 27].
What could be objected to the diagnosis of an ACC of
the liver in our case is the multifocality of the liver
lesions, which is suggestive for metastatic disease. How-
ever, despite thorough work-up no other primary was
found. Furthermore, it is worth noting that ACC is nor-
mally relatively large in size by the time of diagnosis [4],
which makes an occult primary rather unlikely. In
addition, multifocal growth of primary liver tumors is
not unusual, e.g. in intrahepatic CCC [31, 32] and HCC
[33, 34]. Indeed, primary hepatic ACC might originate
from acinar trans-differentiation of biliary progenitor
cells, thus representing the acinar counterpart of hepatic
cholangiocarcinoma [15].
Fig. 6 Comparison of patients with pancreatitis and neoplasm underlying pancreatic panniculitis (a-c): a Patients with neoplastic conditions are
significantly older than patients with pancreatitis (66.0 +/− 13.0 years vs. 44.7 +/− 20.5 years, p < 0.001). b Underlying malignancy is diagnosed
significantly later than underlying pancreatitis (134 +/− 135 days vs. 20 +/− 26 days, p < 0.001). c Tumor patients have significantly higher lipase
levels than pancreatitis patients (16611 +/− 20772 vs. 5324 +/− 14436 U/l, p < 0.01). d Kaplan-Meier plot of survival after appearance of the first
panniculitis lesion in patients with pancreatic panniculitis associated with malignancy. Median survival is 4.75 months (n = 29)
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In an analysis of more than 130 cases of pancreatic
panniculitis described in the last 20 years, we could
show that nearly half of the cases are associated with an
internal malignancy. Current concepts of the patho-
genesis of pancreatic panniculitis suggest a role of pan-
creatic enzymes produced or released by these tumors
[8, 9]. Therefore – though only rarely so named [35] –
pancreatic panniculitis should be regarded as facultative
paraneoplastic condition [36] and a tumor screening,
especially for pancreatic tumors, should always be
included in the diagnostic work-up.
The analysis of different parameters of these cases
revealed significant differences between patients with
pancreatic panniculitis and associated neoplasm or pan-
creatitis. On average, patients with a tumor are older
and have higher lipase levels. Moreover, it takes longer
until a diagnosis is made in these cases. A lipase cut-off
value of 4414 U/l is able to differentiate between under-
lying pancreatitis and neoplasm with a sensitivity and
specificity comparable with CA 19–9 in ductal adenocar-
cinoma vs. benign pancreatic disease [37].
Regarding the epidemiology and the natural course of
malignancy and pancreatitis these results are not very
surprising. However, these items can provide a first
orientation, which etiology has to be primarily sus-
pected. Like this, they may trigger a particularly inten-
sive search for tumors in older patients with high lipase
levels and a long-lasting history of panniculitis.
This is even more important as pancreatic panniculitis
seems to be a hallmark of poor prognosis in tumor pa-
tients. Median survival in the cases with underlying
malignancy and included follow-up data was 4.75 months
after appearance of the first skin lesion.
Of course, this retrospective analysis has significant
limitations as it is exclusively based on case reports.
Though, it is the first systematic evaluation of survival in
pancreatic panniculitis and poor outcome is remarkable,
because over 50 % of the included cases were ACC
patients, which otherwise have considerably better
survival [38, 39].
Due to the rarity of the disease, clear therapeutic algo-
rithms for ACC are missing. Since most of the cases
present with distant metastases only a subset of patients
qualifies for resection [39]. Therefore, cancer therapy is
often limited to palliative approaches like chemotherapy
or ablative treatment. As in our case, patients often suf-
fer heavily from the pain caused by their skin lesions
and analgetic therapy is frequently not sufficiently able
to reduce pain [12, 14, 22, 40, 41]. Thus, palliative treat-
ment strategies are very important for symptom control
as well.
Octreotide has been reported to alleviate symptoms in
some cases [42–44]. Chemotherapeutic agents reported
to be used in patients with pancreatic panniculitis and
underlying ACC include gemcitabine and the FOLFIRI
regime [45, 46]. Furthermore, one case with resolution
of panniculitis following metastasectomy [47] and one
case with marked symptom reduction after transarterial
chemoembolization (TACE) of hepatic metastases [48]
are described in literature. Some success in the treat-
ment of pancreatic ACC has been reported with the use
of FOLFOX [49], FOLFIRINOX [50], cisplatin/etoposide
[51] and gemcitabine in various combinations including
erlotinib [52].
Conclusion
To our best knowledge, this is the first report of pancreatic
panniculitis in a patient with primary ACC of the liver.
The possibility of pancreatic panniculitis should always
be included in diagnostic considerations regarding pan-
niculitic lesions. Therefore, a cutaneous biopsy should
be obtained, pancreatic enzymes should be measured
and abdominal imaging should be performed as early as
possible. When diagnosed, pancreatic panniculitis has to
be regarded as a facultative paraneoplastic syndrome
and appropriate tumor screening or biopsy procedures
have to be undertaken. This is especially important in
older patients with high lipase levels and long-lasting
symptoms. Regarding the presented case, tumors of
extrapancreatic primary must also be considered.
Pancreatic-type ACC is the malignancy most often
associated with pancreatic panniculitis. It can not only
originate from the pancreas but also from the liver,
which can be diagnosed, when other primary sites have
been excluded.
Pancreatic panniculitis in association with malignancy
seems to be linked with poor prognosis. Thus, early
diagnosis is necessary to improve survival and ease
symptoms, e.g. by resection or chemotherapy. Symptom-
atic therapy with octreotide seems worth trying. Further
studies are required to define standard therapeutic strat-
egies for unresectable ACC.
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